AUTHOR=Chen Yi-Xin , Chen Juan , Yin Ji-Ye , Zhou Hong-Hao , He Bai-Mei , Liu Zhao-Qian 

TITLE=Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy

JOURNAL=Frontiers in Pharmacology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.709528

DOI=10.3389/fphar.2021.709528

ISSN=1663-9812

ABSTRACT=<p><bold>Purpose:</bold> Lung cancer is the largest cause of cancer deaths in the world. Platinum-based chemotherapy is a foundation of first-line chemotherapy. However, the prognosis of lung cancer treated with platinum-based chemotherapy is still a challenge. Single nucleotide polymorphism of non-coding RNA has the potential to be a biomarker, but its effectiveness has yet to be comprehensively assessed. In this study, we explored the association between polymorphisms of non-coding RNA and prognosis of lung cancer patients receiving platinum-based chemotherapy.</p><p><bold>Materials and Methods:</bold> For 446 lung cancer patients receiving platinum-based chemotherapy, 22 single nucleotide polymorphisms of microRNA and long noncoding RNA were genotyped by MALDI-TOF mass spectrometry. Cox regression analysis, Kaplan-Meier method, and long-rank test have been performed to assess the association of overall and progression-free survival with polymorphisms.</p><p><bold>Results:</bold> In the additive and dominant models, genetic polymorphism of <italic>ANRIL</italic> rs1333049 (G &gt; C) was significantly associated with progression-free survival. Additive model: CC vs GC vs GG [HR = 0.84, <italic>p</italic> = 0.021, 95% CI (0.73–0.97)]; Recessive model: CC vs GG + GC [HR = 0.77, <italic>p</italic> = 0.026, 95% CI (0.61–0.97)]. In the dominant model, compared with the CC genotype patients, lower risk of death [HR = 0.81, <italic>p</italic> = 0.036, 95% CI (0.66–0.99)] and lower risk of progression [HR = 0.81, <italic>p</italic> = 0.040, 95% CI (0.67–0.99)] have been observed on the patients with CG or GG genotype in <italic>miR-146A</italic> rs2910164.</p><p><bold>Conclusion:</bold> Our research demonstrated the potential of using <italic>ANRIL</italic> rs1333049 (G &gt; C) and <italic>miR-146A</italic> rs2910164 (C &gt; G) as biomarkers to support the prediction of a better prognosis for lung cancer patients receiving platinum-based chemotherapy.</p>